Ferring joins with UCB to promote CIMZIA prefilled syringe for Crohn’s disease in the U.S. Co-promotion strengthens commitment to patients…
Ragans is now responsible for Ferring US commercial, manufacturing and development operations Ragans joined Ferring, a world leader in reproductive…
MEGASET-HR (high responder) study met its primary non-inferiority endpoint, with Menopur-treated patients experiencing a 35.5% ongoing pregnancy rate (OPR) per…
Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3…
Fertility House Calls service offered to residents of Greater Denver metro area as part of a pilot program Personalized service…
The multi-center study met its primary endpoint with 53% of CIS ± Ta/T1 patients achieving a complete response (CR) at…
Ferring launches new company FerGene, with a focus on the global development and US commercialization of nadofaragene firadenovec, for high-grade,…
• Ferring will deliver two oral presentations; one showcasing data from MEGASET-HR and the other discussing the influence of body…
A comprehensive analysis of 22,300 non-patient individuals, of which 24.4% had nocturia (defined by the study as ≥2 urinations per…
Parsippany, New Jersey – 14 June 2019 – Rebiotix and Ferring Pharmaceuticals were saddened to learn about the patients mentioned…